Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

Corrado Barbui, Toshiaki A. Furukawa and Andrea Cipriani
CMAJ January 29, 2008 178 (3) 296-305; DOI: https://doi.org/10.1503/cmaj.070693
Corrado Barbui MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiaki A. Furukawa MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Cipriani MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Can effectiveness be evaluated from efficay studies?
    Paolo Decina
    Posted on: 22 February 2008
  • The Effectiveness of Paroxetine in Depression
    Murray M Finkelstein
    Posted on: 31 January 2008
  • Posted on: (22 February 2008)
    Page navigation anchor for Can effectiveness be evaluated from efficay studies?
    Can effectiveness be evaluated from efficay studies?
    • Paolo Decina

    Sir:

    In their review “Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data” Barbui and colleagues interpret the data as indicating that paroxetine is not superior to placebo in terms of overall treatment effectiveness and acceptability. The primary measure of both effectiveness and acceptability of treatment was the propor...

    Show More

    Sir:

    In their review “Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data” Barbui and colleagues interpret the data as indicating that paroxetine is not superior to placebo in terms of overall treatment effectiveness and acceptability. The primary measure of both effectiveness and acceptability of treatment was the proportion of patients who left the study early for any reason, this taken as a proxy measure of treatment discontinuation.

    The study raises the crucial question of evaluating the effectiveness of a drug from data obtained in trials specifically designed to assess its efficacy. I wonder whether such an evaluation is ever possible. In this case, while readily detectable, the endpoint of dropping out of trials for any reason can hardly be taken as a reliable and valid measure of treatment effectiveness (and thus generalizability) because it does not reproduce the flexibility present in best clinical practice needed to qualify the effectiveness of an intervention. Therefore, although the findings of the study may be interesting, until further specific work on the issue is done, the authors’ conclusions should be interpreted with caution.

    Paolo Decina, MD

    General Practice Psychiatrist, Rome, Italy

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (31 January 2008)
    Page navigation anchor for The Effectiveness of Paroxetine in Depression
    The Effectiveness of Paroxetine in Depression
    • Murray M Finkelstein

    As a family physician, I see many patients with mood disorders, and the SSRIs are an important therapeutic option. I have the clinical impression that they can be very effective and I prescribe them often. I was thus interested to read what a systematic overview revealed about their effectiveness (Barbui et al, 2008).

    I was disappointed and puzzled by the bizarre primary outcome measure, the proportion of patients who...

    Show More

    As a family physician, I see many patients with mood disorders, and the SSRIs are an important therapeutic option. I have the clinical impression that they can be very effective and I prescribe them often. I was thus interested to read what a systematic overview revealed about their effectiveness (Barbui et al, 2008).

    I was disappointed and puzzled by the bizarre primary outcome measure, the proportion of patients who left a study early for any reason, selected by the authors. Consider the ideal situation in which no one in either arm drops out; it would be impossible for the active treatment to be better than placebo, even if all treated subjects went into remission. How can this be a measure of effectiveness?

    In my practice, the biggest challenge is persuading patients to persist with therapy through the first few days of unpleasant side effects until the beneficial effects become manifest. I consider early dropout to be a failure of my persuasive powers, and not an indication that the SSRIs are ineffective. I believe that it is important to distinguish between dropout in the first days of treatment, as a manifestation of predictable and often transitory unpleasant side effects, and delayed dropout which may reflect treatment failure. The authors have failed to stratify their analysis on the time of dropout, and their analysis is thus not informative with respect to dropout for the important endpoints of treatment failure or persistent side effects.

    As a clinician I am primarily interested in the effectiveness of the drug in those who actually take it. It is thus disappointing that the authors gave short shrift to their secondary outcome measures, all of which show significant benefit of active treatment.

    Sincerely,

    Murray M. Finkelstein PhD MDCM CCFP

    Department of Family and Community Medicine

    Mt Sinai Hospital

    Toronto

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 178 (3)
CMAJ
Vol. 178, Issue 3
29 Jan 2008
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
Corrado Barbui, Toshiaki A. Furukawa, Andrea Cipriani
CMAJ Jan 2008, 178 (3) 296-305; DOI: 10.1503/cmaj.070693

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials
Corrado Barbui, Toshiaki A. Furukawa, Andrea Cipriani
CMAJ Jan 2008, 178 (3) 296-305; DOI: 10.1503/cmaj.070693
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies
  • Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
  • Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials
  • Accounting for baseline differences in meta-analysis
  • The Chemical Imbalance Hypothesis: An Evaluation of the Evidence
  • Beneficial and harmful consequences of prepartum and postpartum antidepressant exposure
  • Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials
  • Publication bias: What are the challenges and can they be overcome?
  • Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses
  • EMA must improve the quality of its clinical trial reports
  • Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
  • Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies
  • Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials
  • Effectiveness of selective serotonin reuptake inhibitors
  • Effectiveness of selective serotonin reuptake inhibitors
  • Google Scholar

More in this TOC Section

  • Development and validation of a hospital frailty risk measure using Canadian clinical administrative data
  • The effect of changing screening practices and demographics on the incidence of gestational diabetes in British Columbia, 2005–2019
  • Self-reported sleep disturbances among people who have had a stroke: a cross-sectional analysis
Show more Research

Similar Articles

Collections

  • Topics
    • Drugs: psychotherapeutic
    • Psychiatry & mental health: adult
    • Suicide

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire